Drugs / Ginkgo Diterpene Lactone Meglumine
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02526225 Comparator | Feb 2016 → May 2018 | ischemic stroke | Beijing Tiantan Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03219645 Comparator | Jul → Oct 2017 | ischemic stroke | RenJi Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginkgo Diterpene Lactone Meglumine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03219645 ↗ |
| Known as | GDLM | “Ginkgo diterpene lactone meglumine (GDLM) could improve the functional outcome after acute ischemic stroke (AIS).” PMID 39548582 ↗ Nov 2024 |
| Route | Intravenous | “slow intravenous drip.” NCT02526225 ↗ |